Phaseline

Companies › Cumberland Pharmaceuticals

Cumberland Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Immunology, Respiratory; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ifetroban Sodium
Thromboxane A2 receptor (TP receptor) antagonist
TBXA2RPhase 2Scleroderma, Diffuse; Idiopathic Pulmonary FibrosisJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02682511Ifetroban SodiumPhase 2Scleroderma, DiffuseImmunologyMar 2026
NCT05571059Ifetroban SodiumPhase 2Idiopathic Pulmonary FibrosisRespiratoryJan 2028

From the company's SEC filings

Cash of $4m on 2026-06-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

TBXA2R (1)

Companies with the same targets

iVascular S.L.U.

Companies built like this

Prana Therapies Enveda Therapeutics Avalyn Pharma Contineum Therapeutics ReAlta Life Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.